Treating Blood Cancers

David Sallman, MD, Moffitt Cancer Center, Tampa, FL Recorded on April 9, 2026 David Sallman, MD Associate Member, Department of Malignant Hematology Moffitt Cancer Center Tampa, FL In this exciting episode, Dr. David Sallman from Moffitt Cancer Center takes a deep dive into acute myeloid leukemia (AML) and the advances transforming patient care. The discussion spans newly approved therapies, including menin inhibitors, as well as promising approaches under investigation in clinical trials, and explores how these innovations are influencing treatment selection, transplantation, and the management of side effects and complications in today’s AML landscape. Tune in today for expert insight into what’s shaping the future of AML care. Additional Blood Cancer United Resources: Blood Cancer United Accredited and Non-Accredited Healthcare Professional EducationBlood Cancer United Resources for Patients This episode is supported by Kura Oncology, Inc.

Matthew Loscalzo, LCSW, APOS Fellow, City of Hope, Duarte, CA Recorded on March 30, 2026 Matthew Loscalzo, LCSW, APOS Fellow Founding Executive Director and Professor Emeritus of Supportive Care Medicine and Professor of Population Sciences City of Hope Duarte, CA In this episode, licensed clinical social worker Matthew Loscalzo explores how survivors and healthcare professionals often define “normal” differently after treatment. He discusses the emotional shifts that impact relationships, work, and future planning, and shares how healthcare professionals can support meaningful conversations and shared decision-making after treatment ends. Tune in to hear practical insights for supporting patients beyond treatment. Mentioned on this episode: Additional Blood Cancer United Resources: Blood Cancer United Accredited and Non-Accredited Healthcare Professional EducationBlood Cancer United Resources for Patients

Amy Pierre, MSN, ANP-BC, Flatiron Health and Memorial Sloan Kettering, New York, NY and Peter Voorhees, MD, Levine Cancer Institute, Charlotte, NC Recorded on March 10, 2026 Amy Pierre, MSN, ANP-BC Senior Clinical Director, Research Oncology, Flatiron Health Nurse Practitioner, Memorial Sloan Kettering Cancer Center New York, NY Peter Voorhees, MD Director, Outreach for Hematologic Malignancies, Plasma Cells Disorder Program, Department of Hematologic Oncology and Blood Disorders Levine Cancer Institute Charlotte, NC Professor, Cancer Medicine Wake Forest University School of Medicine Winston-Salem, NC In this episode, Dr. Peter Voorhees from the Levine Cancer Institute and Amy Pierre, MSN, RN, ANP BC from Flatiron Health and Memorial Sloan Kettering, break down the evolving landscape of myeloma, from early signs and diagnostic criteria to frontline therapy, transplant decisions, and T- cell redirecting therapies. They explore real world challenges in survivorship, treatment toxicity, and disparities in access to advanced therapies, offering practical insights to help care teams support patients more effectively. Tune in for an informative and forward looking discussion shaping the future of myeloma management. Blood Cancer United Resources: Blood Cancer United Accredited and Non-Accredited Healthcare Professional EducationBlood Cancer United Resources for Patients

Matthew Kutny, MD, University of Alabama, Birmingham, AL, Julie Guillot, Pediatric AML parent, global advocate, and Blood Cancer United Volunteer, and Kelly Laschinger, MSN, RN, CPNP, CPHON, Blood Cancer United, Washington, DC Recorded on February 19, 2026 Matthew Kutny, MD Professor of Pediatrics Director, Leukemia, Lymphoma and Histiocytosis Program Director, Pediatric Clinical Trials Office Institutional Principal Investigator, Children’s Oncology Group (NCI NCTN) Pediatric Hematology and Oncology University of Alabama at Birmingham Birmingham, AL Julie Guillot Pediatric AML parent, global advocate, and Blood Cancer United Volunteer Kelly Laschinger, MSN, RN, CPNP, CPHON Director, Clinical Trial Support Center Blood Cancer United Washington, DC In this episode, Dr. Matthew Kutny from the University of Alabama, and Kelly Laschinger, CPNP and Julie Guillot from Blood Cancer United, break down what clinicians and families need to know about Expanded Access (EA), also known as Compassionate Use, in treating pediatric oncology patients. They clarify key terms, outline when EA should be considered, and walk through how the process works in real-world practice. Their conversation also addresses common barriers, from institutional requirements to sponsor approval, and highlights how pediatric care teams and advocates can work together to navigate them. Tune in for an informative and insightful conversation to help healthcare professionals better understand and utilize Expanded Access! Blood Cancer United Resources: Clinical Trial Support CenterInformation Resource CenterDare to Dream ProjectPediatric Acute Leukemia Master Clinical Trial (PedAL) Mentioned on this episode: Project Facilitate This episode is supported by the Tom Reich Educational Endowment Fund.

Brad Kahl, MD, Siteman Cancer Center, St. Louis MO Recorded on January 27, 2026 Brad Kahl, MD Professor of Medicine Division of Oncology, Department of Medicine Washington University School of Medicine Director, Lymphoma Program Siteman Cancer Center St. Louis, MO In this episode, join Dr. Brad Kahl, Director of the Lymphoma Program at the Siteman Cancer Center in St. Louis, Missouri, as he delivers a concise and practical overview of chronic lymphocytic leukemia (CLL), from initial disease presentation to key diagnostic considerations. Dr. Kahl discusses the prognostic value of cytogenetic testing and its impact on treatment selection and reviews currently approved therapeutic options alongside notable updates from the latest American Society of Hematology (ASH) meeting. He also examines emerging agents and ongoing clinical trials that are shaping the future CLL treatment landscape. The conversation further explores strategies for managing side effects, addressing complications, and supporting patients and caregivers. Tune in for this timely and informative discussion! Additional Blood Cancer United Resources: Blood Cancer United Accredited and Non-Accredited Healthcare Professional EducationBlood Cancer United Resources for Patients

Pam Simon, MSN, CPNP, CPON, Stanford Adolescent and Young Adult Cancer Program (SAYAC), Palo Alto, CA and H. Irene Su, MD MSCE, University of California San Diego, San Diego, CA Recorded on January 20, 2026 Pam Simon, MSN, CPNP, CPON Nurse Practitioner & Program Manager Stanford Adolescent and Young Adult Cancer Program (SAYAC) Palo Alto, CA H. Irene Su, MD MSCE Professor Reproductive Endocrinology and Infertility Fellowship Director Division of Reproductive Endocrinology and Infertility Co-Director, Center for Obstetrics and Gynecology Research Innovations Department of Obstetrics, Gynecology and Reproductive Sciences Director, Moores Cancer Center Leadership Academy University of California San Diego San Diego, CA In this episode, we’re joined by Dr. Irene Su, Professor of Obstetrics, Gynecology, and Reproductive Sciences at UC San Diego, and Pam Simon, Nurse Practitioner and Program Manager of the Stanford Adolescent and Young Adult (AYA) Cancer Program at Stanford Medicine. They discuss fertility risk across treatment types, approaches to fertility preservation and reproductive survivorship planning, insurance and access considerations, and the cultural and sociodemographic factors that shape care. They also share strategies to support shared decision-making and promote psychosocial well being for AYA patients and survivors. Tune in for practical insights to strengthen your approach to fertility care for AYAs. Mentioned on this episode: OncofertilityRisk.comThe Alliance for Fertility Preservation Additional Blood Cancer United Resources: Blood Cancer United Accredited and Non-Accredited Healthcare Professional EducationBlood Cancer United Resources for Patients

Chelsey Winegar, LCSW, MBA, Intermountain Health, Murray, UT Recorded on January 8, 2026 Chelsey Winegar, LCSW, MBA Manager of Oncology Services Intermountain Health Murray, UT Join Chelsey Winegar, LCSW and Manager of Oncology Services at Intermountain Health in Murray, UT, as she breaks down the key differences between burnout and compassion fatigue, and why understanding both is essential for the well being of healthcare professionals and the patients they serve. Chelsey shares practical strategies for recognizing early warning signs, monitoring staff wellness, and building supportive, stigma free environments. The episode also highlights resources and education to help clinicians maintain resilience in demanding clinical settings. Listen in to learn more today! Mentioned on this episode: Trauma Stewardship Additional Blood Cancer United Resources: Blood Cancer United Accredited and Non-Accredited Healthcare Professional EducationBlood Cancer United Resources for Patients

Lore Gruenbaum, PhD, Blood Cancer United, Washington, DC Recorded on December 18, 2025 Lore Gruenbaum, PhD Chief Scientific Officer & Senior Vice President of Research Blood Cancer United Washington, DC Join Dr. Lore Gruenbaum, Chief Scientific Officer and Senior Vice President of Research at Blood Cancer United, to provide practice-changing data in hematologic malignancies from the 67th American Society of Hematology (ASH) Annual Meeting. Explored are breakthroughs in multiple myeloma, AML, CLL, and advances in cell therapy. Discussion also covers the growing use of artificial intelligence to accelerate precision medicine, spotlighting the Blood Cancer United Beat AML® Master Clinical Trial as a model for AI-driven trial design and real-time clinical decision-making. Tune in today for the key takeaways you need to know! Additional Blood Cancer United Resources: Blood Cancer United Accredited and Non-Accredited Healthcare Professional EducationBlood Cancer United Resources for Patients

Raymond Mailhot, MD, MPH, University of Miami, Miami, FL Recorded on December 2, 2025 Raymond Mailhot, MD, MPH Department of Radiation Oncology University of Miami Miami, FL Join us with Dr. Raymond Mailhot from the University of Miami as we explore how social determinants of health shape patient experiences, treatment decisions, and outcomes. He discusses the importance of cultural competence in delivering equitable, patient-centered care and shares practical communication strategies to better engage patients and collaborate effectively. This episode offers actionable insights to strengthen relationships and improve overall care quality. Tune in today to gain practical strategies that will enhance your approach to patient-centered care and drive better outcomes! Additional Blood Cancer United Resources: Blood Cancer United Accredited and Non-Accredited Healthcare Professional EducationBlood Cancer United Medical Debt Case Management Program for PatientsBlood Cancer United Additional Resources for Patients

Paul J. Hampel, MD, Mayo Clinic, Rochester, MN Recorded on November 4, 2025 Paul J. Hampel, MD Assistant Professor of Medicine Division of Hematology, Department of Medicine Mayo Clinic Rochester, MN In this episode, Dr. Paul Hampel from Mayo Clinic Rochester takes a comprehensive look at hairy cell leukemia (HCL). He reviews the current diagnostic work-up, […]

Michael J. Mauro, MD, Memorial Sloan Kettering Cancer Center, New York, NY Recorded on October 23, 2025 Michael J. Mauro, MD Director, Chronic Myeloid Leukemia Program Professor of Medicine, Leukemia Service Memorial Sloan Kettering Cancer Center New York, NY Tune in for this expert-led discussion with Dr. Michael Mauro from Memorial Sloan Kettering Cancer Center […]

Rahul Banerjee, MD, FACP, Fred Hutchinson Cancer Center, Seattle, WA Recorded on September 25, 2025 Rahul Banerjee, MD, FACP Assistant Professor Fred Hutchinson Cancer Center Seattle, WA In this episode, Dr. Rahul Banerjee from Fred Hutchinson Cancer Center in Seattle, WA, discusses the evolving role of measurable residual disease (MRD) in hematologic malignancies. He explores […]

Ann Collins, PA, Blood Cancer United, Washington, DC, Kelly Laschinger, MSN, RN, CPNP, CPHON, Blood Cancer United, Washington, DC, Sarah K. Tasian, MD, Children’s Hospital of Philadelphia, Philadelphia, PA Recorded on September 9, 2025 Ann Collins, PA Project Leader, Pediatric Acute Leukemia Master Clinical Trial (PedAL) Blood Cancer United Washington, DC Kelly Laschinger, MSN, RN, […]

Catherine Lai, MD, MPH, University of Pennsylvania Perelman Center for Advanced Medicine, Philadelphia, PA Recorded on June 27, 2025 Catherine Lai, MD, MPH Associate Professor Physician Leader, Leukemia Clinical Research Unit University of Pennsylvania Perelman Center for Advanced Medicine Philadelphia, PA In this episode, Dr. Catherine Lai, from the University of Pennsylvania’s Perelman Center for Advanced Medicine, joins us to discuss the current landscape of adult acute lymphoblastic leukemia (ALL) treatment. She highlights recent advances in frontline and relapsed therapies, the critical role of measurable residual disease (MRD), and the use of immunotherapy and targeted treatments. Dr. Lai further explores transplant considerations, management of side effects, and tailored approaches for B-cell and T-cell ALL. She also emphasizes patient-centered care, including strategies for end-of-life discussions and shared decision-making. Tune in today for expert insights and practical takeaways on the evolving future of ALL care!

Uma Borate, MBBS, MS, The Ohio State University, Cleveland, OH Recorded on May 27, 2025 Uma Borate, MBBS, MS Associate Professor, Division of Hematology Acute Leukemia Clinical Research Disease Group Leader The Ohio State University Cleveland, OH What’s changing in acute myeloid leukemia (AML)? Join Dr. Uma Borate from The Ohio State University in Columbus, Ohio, as she dives into emerging breakthroughs in AML biology, including molecular drivers, menin inhibitors, and the challenges of developing bispecifics and CAR T-cell therapies. She also shares updates from the LLS Beat AML® Master Clinical Trial and ongoing clinical trials, and reflects on the evolving treatment landscape across age groups. Don’t miss this dynamic conversation packed with expertise and hope for the future of AML!

Aaron Gerds, MD, MS, Cleveland Clinic, Cleveland, OH Recorded on May 13, 2025 Aaron Gerds, MD, MS Associate Professor of Medicine Cleveland Clinic Lerner College of Medicine Case Western Reserve University School of Medicine Medical Director Case Comprehensive Cancer Center Clinical Research Office Cleveland, OH In this episode, Dr. Aaron Gerds from the Cleveland Clinic explores the intricacies of Myeloproliferative Neoplasms (MPNs), from diagnosis and monitoring to treatment goals and the latest therapeutic advances. Dr. Gerds discusses emerging therapies, the significance of clinical trials, strategies for managing side effects and long-term effects, and valuable resources for healthcare professionals, patients, and families. Tune in today for expert insights on MPNs! This episode is supported by GSK plc and Karyopharm Therapeutics.

Tessa Faye Flores, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY Recorded on April 24, 2025 Tessa Faye Flores, MD Medical Director, Cancer Screening and Survivorship Roswell Park Comprehensive Cancer Center Buffalo, NY We are pleased to celebrate the 100th episode of Treating Blood Cancers with Dr. Tessa Flores from Roswell Park Comprehensive Cancer Center in Buffalo, New York, as she shares insights into survivorship care. In this episode, Dr. Flores explores the different phases of survivorship and the psychosocial challenges that accompany each stage. She highlights the vital role of a collaborative care team, including primary care practitioners, in supporting survivors of cancer to achieve and maintain a healthy post-treatment life. As the number of survivors continues to grow, the focus on long-term wellness becomes increasingly important. Dr. Flores emphasizes, “A tenet of survivorship care is preventive care”. Tune in for this special episode and join the conversation today! This episode is supported by Genentech, A Member of the Roche Group. Additional Episodes on Survivorship Care:

Mikkael A. Sekeres, MD, MS, University of Miami Sylvester Comprehensive Cancer Center, Miami, FL Recorded on April 17, 2025 Mikkael A. Sekeres, MD, MS Chief, Division of Hematology Professor of Medicine Sylvester Comprehensive Cancer Center University of Miami Miami, FL Join us with Dr. Mikkael Sekeres of the University of Miami Sylvester Comprehensive Cancer Center as he explores the complexities of diagnosing and treating Myelodysplastic Syndromes (MDS), including “watch and wait.” Through case-based discussion, he highlights advances in high-risk MDS management, from novel targeted therapies to stem cell transplantation and clinical trials. Dr. Sekeres also shares strategies for managing side effects and emphasizes the importance of multidisciplinary care in improving patient outcomes. Tune in to gain valuable insights on MDS today!

Jeffrey Magee, MD, PhD, Washington University School of Medicine, St. Louis, MO Recorded on April 3, 2025 Jeffrey Magee, MD, PhD Elizabeth H. and James S. McDonnell III Professor of Pediatrics Director, McDonnell Pediatric Cancer Center Division of Pediatric Hematology and Oncology Washington University School of Medicine St. Louis, MO In this episode, we sit down with Dr. Jeffrey Magee from the McDonald Pediatric Cancer Center at the Washington University School of Medicine in St. Louis to discuss the evolving landscape of pediatric blood cancers. Reflecting on his work, Dr. Magee shares, “One of the things I really love about the job is that it operates right at the interface between the science and the professional practice of medicine.” He examines groundbreaking advances bringing new hope to children and their families, from novel therapies and CAR T-cell therapy to the crucial role of clinical trials. Dr. Magee also speaks candidly about the challenges of delivering difficult news and shares compassionate strategies for supporting families through their toughest moments. Join us for this insightful and informative conversation on the future of pediatric blood cancer care today!

Angela Dispenzieri, MD, Mayo Clinic, Rochester, MN Recorded on March 18, 2025 Angela Dispenzieri, MD Consultant, Division of Hematology Serene M. and Frances C. Durling Professor of Medicine and of Laboratory Medicine and Pathology Mayo Clinic Rochester, MN Join us as we dive into in the complex care of amyloid and myeloma with Dr. Angela Dispenzieri from Mayo Clinic Rochester, Minnesota. She explains the diagnosis and explores the differences between amyloid and myeloma. Discussion on treatment strategies for complex cases, side effects of therapies, and difficult conversations with patients, provide practical information on patient care. Tune in today to learn more about the complexities of myeloma. This episode is supported by GSK plc.